Pharmaceutical combination

摘要

A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.

主权项

1. A pharmaceutical combination comprising as components:
(a) (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound of formula (I′),or a pharmaceutically acceptable acid addition salt thereof, whereby the acid addition salt is hydrochloride, and
(b) at least one NMDA-antagonist selected from the group consisting of (R,S)-ketamine, (S)-ketamine and memantine, or a pharmaceutically acceptable acid addition salt thereof; wherein components (a) and (b) are present in such a weight ratio that the composition exerts a synergistic effect upon administration to a patient.